Search Results
Your search for ,LAB matches 1001 pages
Showing 601 - 650Once a Vocational Nomad, Christine H. Chung, MD, Now Works to Promote Patient-Centered Care in Head and Neck Cancer
Christine H. Chung, MD, Chair of the Department of Head and Neck-Endocrine Oncology at Moffitt Cancer Center, Tampa, Florida, was born and reared in Seoul, Republic of Korea. Dr. Chung immigrated with her mother and two brothers to Los Angeles, where her family then resided. Dr. Chung did not speak ...
With an Illustrious Career in Breast Oncology, Daniel F. Hayes, MD, FASCO, Follows in the Footsteps of Giants as ASCO President-Elect
ASCO President-Elect Daniel F. Hayes, MD, FASCO, was born in Shelbyville, Indiana, a small city in the center of the state. “My dream was to become a high school basketball and track and field coach; my older brother wanted to be a doctor, and his ambitions also began in first grade,” revealed Dr....
Maximizing Cancer Cure: How Do We Get There?
Is cancer really “curable,” and if so, how? For a “Cancer Dialogue” held during the 2016 American Association of Cancer Research (AACR) Annual Meeting, half a dozen stellar participants from the research, industry, regulatory, and advocacy communities convened to debate the topic. The ASCO Post was ...
City of Hope Awarded $2.5 Million Grant to Launch Nutrition Initiative
Funded by a $2.5 million grant from the Conrad N. Hilton Foundation, City of Hope has launched a 5-year initiative to reduce cancer risk in the Los Angeles area by promoting healthy eating and physical activity, particularly among school children. The long-range plan is to replicate the...
Larry W. Kwak, MD, PhD, Awarded Ho-Am Prize in Medicine
Physician and scientist Larry W. Kwak, MD, PhD, Director of City of Hope’s Toni Stephenson Lymphoma Center, has been awarded the 2016 Ho-Am Prize in Medicine, which recognizes people of Korean heritage who have made impressive contributions in clinical and research areas that contributed to the...
The Time Is Now for the Worldwide Cancer Community to Be Proactive
The ASCO Post recently spoke with nationally recognized surgical oncologist Chandrakanth Are, MBBS, MBA, FRCS, FACS, Jerald L & Carolynn J. Varner Professor of Surgical Oncology & Global Health; Vice Chair of Education; and Program Director, General Surgery Residency, University of Nebraska ...
Obinutuzumab in Relapsed or Refractory Follicular Lymphoma
On February 26, 2016, obinutuzumab (Gazyva) was approved for use in combination with bendamustine (Bendeka, Treanda) followed by obinutuzumab monotherapy for treatment of patients with follicular lymphoma who have relapsed after or are refractory to a rituximab (Rituxan)-containing regimen.1,2...
Surgeons—Yes, Surgeons—Have a Role in Translational Cancer Research
Surgeons are clearly more comfortable in the operating room than the laboratory, but there is a place for them in translational cancer research as well, according to one surgeon who has led cutting-edge research in pancreatic cancer. “Translational studies require access to patients, to tissue, and ...
Single Dose of Trastuzumab Kickstarts Immune Response in Certain Breast Cancers
A tumor’s immune response to a single dose of the HER2 inhibitor trastuzumab (Herceptin) predicted which patients with HER2-positive breast cancer would respond to the drug on a more long-term basis, according to the results of a study published by Varadan et al in Clinical Cancer Research....
Carfilzomib Plus Dexamethasone in Previously Treated Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 21, 2016, carfilzomib (Kyprolis) was approved for use in ...
Nivolumab Plus Ipilimumab in Unresectable or Metastatic Melanoma Regardless of BRAF Mutation Status
On January 23, 2016, the indication for nivolumab (Opdivo) plus ipilimumab (Yervoy) in unresectable or metastatic melanoma was expanded through accelerated approval to include patients regardless of BRAF V600 mutation status.1 The combination was previously approved for treatment of patients with...
Study Finds Mechanism by Which Obesity Promotes Pancreatic and Breast Cancers
Massachusetts General Hospital (MGH) investigators may have uncovered a novel mechanism behind the ability of obesity to promote cancer progression. In their report published by Incio et al in Clinical Cancer Research, the research team describes finding an association between obesity and an...
Expanded Approval of Pembrolizumab in Unresectable or Metastatic Melanoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 18, 2015, approval of the programmed cell death...
Terence S. Dermody, MD, Named Chair of Pediatrics at UPMC and Scientific Director of Children’s Hospital of Pittsburgh
Terence S. Dermody, MD, has been named the Chair of the Department of Pediatrics at the University of Pittsburgh School of Medicine and Physician-in-Chief and Scientific Director at Children’s Hospital of Pittsburgh of the University of Pittsburgh Medical Center (UPMC). Dr. Dermody will officially...
Blood Test Can Predict High-Risk Cancers in Patients Treated With CAR-T
Dramatic advances have been made in using genetically engineered chimeric antigen receptor–modified T cells (CAR-T) with anti-CD19 specificity to treat highly refractory hematologic malignancies. The highest complete remission rates have been achieved in patients with relapsed or refractory acute...
Venetoclax May Prove to Be Strong Weapon Against Poor-Prognosis Chronic Lymphocytic Leukemia
Venetoclax, the latest entry into the field of treatment of chronic lymphocytic leukemia (CLL), is a powerful investigational therapy that promises to fill an important niche: treatment of high-risk relapsed/refractory patients with deletions of 17p. Nearly 80% of patients with relapsed/refractory...
Severe Toxicities Seen in Younger Patients Receiving Front-Line Idelalisib for Chronic Lymphocytic Leukemia
Hematologists and patients with chronic lymphocytic leukemia (CLL) are excited about new drugs that have dramatically improved outcomes. But all drugs have side effects, and it is important to be aware of potential consequences. Hepatotoxicity turns out to be a major concern in younger CLL patients ...
Elotuzumab in Previously Treated Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 30, 2015, elotuzumab (Empliciti) was approved for...
A Conversation with David Henry, MD
Given the intricate nature of oncology workflow, terminology, cancer staging, and the high risk associated with chemotherapy administration, an oncology electronic medical record (EMR) system needs to be much more than a storehouse of patient information. According to David Henry, MD, Clinical...
Integrative Medicine Offers Added Value for Patients with Cancer
Addressing a patient’s physical, emotional, and spiritual needs during the cancer journey, integrative medicine combines such time-honored therapies as nutrition, exercise, and meditation alongside allopathic approaches to cancer care, with the ultimate goal of improving survival rates and reducing ...
Need for Data Capture Crucial, Now and After ‘Meaningful Use’
It’s never enough. Whether it is the Centers for Medicare & Medicaid Services (CMS), other payers, pharmaceutical manufacturers, or specialty companies, one can never provide enough data. When will it all end? The problem, or the opportunity for many, is that it won’t end. The need for discrete ...
MD Anderson Cancer Center’s New President Has a Bold Vision
On September 1, 2011, Ronald A. DePinho, MD, became only the fourth President in the 70-year history of The University of Texas MD Anderson Cancer Center in Houston. Dr. DePinho spent the previous 14 years as head of Dana-Farber’s Belfer Institute for Applied Cancer Science. In a recent interview...
Data on Watchful Waiting for Low-risk Prostate Cancer May Swing Focus to Higher-risk Tumors and Quality of Life
Surgery did not increase survival rates compared to watchful waiting in men with clinically localized prostate cancer. Results were particularly strong for men with prostate-specific antigen (PSA) levels of 10 ng/dL and under, and those who have low-risk disease, according to data from the Prostate ...
Vandetanib Demonstrates Therapeutic Efficacy in Patients with Advanced Medullary Thyroid Cancer
A phase III trial among patients with locally advanced or metastatic medullary thyroid cancer met its primary objective of progression-free survival prolongation among patients receiving vandetanib compared to placebo. The secondary efficacy endpoints of objective response rate, disease control...
Overexpression of p16 Does Not Indicate Increased Risk of Breast Cancer in Women with Atypical Hyperplasia
Women diagnosed with atypical hyperplasia have a substantial risk of subsequent development of breast cancer, with a cumulative incidence of approximately 30% at 25 years. Atypical hyperplasia is considered to be a precursor to ductal carcinoma in situ (DCIS). p16 (a nuclear protein encoded by the...
Impact of p53 Status on Cancer Treatment Selection
Wild-type p53 emerges from a latent state and becomes stabilized and activated in response to genotoxic and cellular stress signals, resulting in the transcriptional modulation of multiple genes involved in regulating cell-cycle progression, senescence, and apoptosis. More than 50% of human tumors...
Targeting AKT/mTOR May Improve Response to Monoclonal Antibodies in Some Cancers
The insulin-like growth factor (IGF) network plays a central role in regulating tumor cell growth and differentiation, tumor angiogenesis, metastasis, apoptosis, and multidrug resistance. Increased IGF-1 receptor (IGF-1R) expression and circulating IGF-1 are associated with increased risk for...
Expert Point of View: Dual HER2 Blockade Substantially Delays Disease Progression
The availability of effective therapies for HER2-positive tumors has made breast cancer a better managed disease, but outcomes could be further enhanced through the targeting of other players in this pathway, emerging data suggest. C. Kent Osborne, MD, of Baylor College of Medicine, Houston,...
Combination of Oncolytic Virus and Chemotherapy Holds Promise in Glioblastoma
Glioblastoma remains a uniformly lethal disease. Both the alkylating agent temozolomide and oncolytic viruses (engineered to preferentially infect and kill cancer cells) hold promise in treatment of glioblastoma. The effects of combining the two and the mechanisms of their interaction on cancer...
Six1-Eya2 Interaction a Potential Target in Blocking Breast Cancer Metastasis
The Six1 gene is a key regulator of embryonic development that requires interaction with the Eya family of proteins (Eya1-4) to activate transcription of genes involved in neurogenesis, myogenesis, and nephrogenesis. Overexpression of Six1 and Eya is observed in a number of cancers. In breast...
Significant Differences in Genetic Characteristics of Primary Colorectal Cancer and Hepatic Metastases
Vermaat and colleagues from the University Medical Center Utrecht, Hubrecht Institute, Utrecht, The Netherlands, and Hoffman-La-Roche Inc./Genentech, Nutley, New Jersey, recently showed that there was significant genetic variation between individual primary colorectal cancer tumors and their...
PI3K Inhibitors May Improve Response to Cancer Immunotherapy
The induction of antitumor immunity by vaccines or immunotherapies is inhibited by the immunosuppressive microenvironment of tumors. Toll-like receptor (TLR) agonists have the potential to increase inflammatory antitumor effects in the microenvironment, but these ligands can exert a mixture of both ...
Androgen Deprivation Therapy May Lead to Castration Resistance in Prostate Cancer
Although androgen-deprivation therapy is effective in inducing regression of androgen-dependent prostate cancer, relapse often occurs in an androgen-independent manner and is associated with poor prognosis. The mechanisms underlying castration resistance are not fully understood. Sung and...
Targeted Mutations in ATR Pathway and Implications for Combination Strategies
Many chemotherapy agents work by causing DNA strand breaks or accumulation of DNA replication intermediates. ATR (ataxia-telangiectasia mutated and Rad 3-related protein) is a potential target for combination drug strategies, because signaling of this protein in response to such altered DNA...
Targeted Massively Parallel Sequencing Identifies Clinically Relevant Alterations in Cancer Genes
Systematic methods for profiling tumor genomic alterations remain underdeveloped, with current clinical profiling usually being confined to identification of limited numbers of oncogene point mutations. At present, there is no systematic technique for interrogating tumor samples in situ for a...
SMAC Mimetics Induce Proinflammatory Cancer Cell Death and Adaptive Antitumor Immune Response
SMAC/DIABLO (second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI) is a proapoptotic mitochondrial protein that is released in response to various apoptotic stimuli. Molecular mimetics of SMAC are being investigated for use in cancer treatment,...
Bone Morphogenesis Protein 4 Pathway as Treatment Target in Hepatocellular Carcinoma
Bone morphogenesis protein 4 (BMP4), which belongs to the transforming growth factor (TGF)-β family, is a multifunctional cytokine that is known to be involved in human carcinogenesis. The cytokine exerts its effects through pathways dependent on and independent of SMAD proteins, which are the...
Targeting Human Endogenous Retrovirus K Envelope Protein Inhibits Breast Cancer Growth
The human genome contains a large variety of endogenous retroviral sequences (approximately 8% of the genome). Although most of these are highly defective, the human endogenous retrovirus type K (HERV-K) family shows conservation of apparently intact retroviral genes and is transcriptionally active ...
PEDF Has Cytotoxic Effect on Breast Cancer Cells and Neuron-protective Effect
The cytokine pigment epithelium–derived factor (PEDF) is downregulated in brain metastases of breast cancer by approximately 14-fold compared with primary breast tumors, suggesting that promoting its expression might inhibit metastatic spread. Normal breast epithelial cells express high levels of...
ASCO Continues to Support Oncologists in Electronic Health Records Adoption at 2012 Annual Meeting
As part of its ongoing effort to support oncology practices in adopting Electronic Health Records (EHR) to improve their quality of care, ASCO is holding its sixth annual EHR Vendor Lab, from June 2-4 at the 2012 ASCO Annual Meeting in Chicago. This resource gives attendees the opportunity to test...
Inhibition of IL-8 Receptor Reduces Colorectal Cancer Proliferation and Sensitizes the Disease to Oxaliplatin
Recent studies have shown that interleukin-8 (IL-8) and its receptors CXCR1 and CXCR2 are significantly upregulated in colorectal cancer tumors and their microenvironment and act as regulators of proliferation, angiogenesis, and metastasis. Ning and colleagues from the University of Southern...
Characteristics of Field Cancerization in Histologically Normal Tissue Adjacent to Breast Tumors
It has been shown that a field of genetically altered but histologically normal tissue extends 1 cm or more from the margins of human breast tumors. The characteristics of this field are not fully understood, although it is clear that the molecular alterations in affected cells could provide...
New Research Shows Promise in Cachexia, a Persistent Clinical Challenge
In the late 1980s, researchers led by Alfred L. Goldberg, PhD, first isolated the large protein complexes now called 26S proteasomes, which are the sites where most cellular proteins are degraded back to amino acids. Protein degradation by the proteasome pathway is critical in regulating many...
Progress in Treating Chronic Lymphocytic Leukemia Has Led to Across-the-board Improvements in Survival
Four decades ago, Kanti R. Rai, MD, was determined to figure out why some of his patients with chronic lymphocytic leukemia (CLL) died within 2 years after their diagnosis, while others lived for 20 or even 30 years. At the time, Dr. Rai was a young scientist doing research in leukemia at...
Regional Infusion of Designer T Cells to Treat Intrahepatic Metastases
Designer T cells are modified from normal T cells to express specific immune receptors that allow them, via antibody-directed recognition or other mechanisms, to kill malignant cells bearing particular antigens. The Surgical Immunotherapy Lab at the Roger Williams Medical Center, Providence, Rhode...
Anti-EpCAM Antibody-Drug Conjugate Shows High Activity against Pancreatic Cancer
Human epithelial cell adhesion molecule (EpCAM) is overexpressed in many cancers. Although anti-EpCAM antibodies have shown promise in preclinical studies, early-phase clinical evaluation of these antibodies has been disappointing. To determine whether the antitumor activity of anti-EpCAM antibody...
Gab2 Promotes Characteristics of Epithelial-to-Mesenchymal Transition in Ovarian Cancer
Ovarian cancer is often diagnosed at a late stage, when cancer cells have already migrated and invaded other tissues and organs. Wang and colleagues from the University of Colorado Denver and the Dana-Farber Cancer Institute in Boston, showed that Gab2—a scaffolding adaptor protein that is...
Complex Relationship between Metformin and BRAF-mutant Tumors
The antidiabetic drug metformin appears to lower cancer risk in diabetic patients and has shown antitumor activity in preclinical studies. Suppression of mTOR signaling via AMP kinase (AMPK)-dependent TOR complex 1 (TORC1) inhibition is one of the proposed mechanisms by which metformin appears to...
Pretreatment Tumor Hypoxia Predicts Biochemical Failure after Radiotherapy for Prostate Cancer
Hypoxia often occurs early in solid tumor development as a result of imbalances between oxygen supply and consumption and may lead to genetic and molecular signaling that influences the biology and clinical behavior of tumors and response to treatment. Milosevic and colleagues from Princess...
Markers in Cancer 2012, to be Held October 11–13, Will Seek to Move the Field of Biomarkers to the Next Phase
There are hundreds and hundreds of papers published on biomarkers in cancer each year, but very few make it over the hurdles necessary to be used in actual patient care, said James L. Abbruzzese, MD, Chair of the Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson ...
